hVIVO shares jump 7% on £6m flu trial contract, boosting 2026 revenue outlook

hVIVO PLC's shares rose 7% to 7.99p following a £6 million contract to conduct an influenza human challenge trial, marking continued recovery with a 25% gain since early 2026. This deal adds to recent contracts, including a large phase III Bordetella pertussis trial with ILiAD Biotechnologies, enhancing revenue visibility for 2026. Despite a revenue drop and operating losses in 2025 after acquiring CRS, hVIVO is expected to grow revenue by 7.5% to £50.3 million in 2026 and return to operating profit by 2027. The company remains financially stable with £14.3 million net cash and no debt, positioning it well for recovery and growth in the niche human challenge trial market.